The 340B Drug Pricing Program: Evolution and Looking Forward
Published 2019
Since 1992, the 340B Drug Pricing Program has played a modest, but increasingly important, role in the U.S. healthcare market. This whitepaper provides a brief overview of the program since inception; the impact of the program on various stakeholders; and presents a forward-looking view on the program given recent public reports and discussion, administration actions and potential legislative changes.
Enter your name and email address to download the publication:
![](/getmedia/d6e252fe-8022-4405-9ebc-471fe688d6ca/340B-Whitepaper.png?width=490&height=648&ext=.png)